{"id":"https://openalex.org/W62627980","doi":null,"title":"Impact of a Restrictive Reimbursement Policy on Access, Costs and Quality & Safety of treatment: Analysis of a Dutch reimbursement case regarding GLP-1 therapy","display_name":"Impact of a Restrictive Reimbursement Policy on Access, Costs and Quality & Safety of treatment: Analysis of a Dutch reimbursement case regarding GLP-1 therapy","publication_year":2012,"publication_date":"2012-08-30","ids":{"openalex":"https://openalex.org/W62627980","mag":"62627980"},"language":"en","primary_location":{"id":"mag:62627980","doi":null,"is_oa":false,"landing_page_url":"https://thesis.eur.nl/pub/12738/Buitenhuis%20R%20351371.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011305507","display_name":"R. Buitenhuis.","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"R. Buitenhuis.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5011305507"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.6937,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.80396879,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9297000169754028,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9297000169754028,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.03139999881386757,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.02810000069439411,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.921999990940094},{"id":"https://openalex.org/keywords/drug-reimbursement-policy","display_name":"drug reimbursement policy","score":0.8899999856948853},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8379999995231628},{"id":"https://openalex.org/keywords/access-to-treatment","display_name":"access to treatment","score":0.8790000081062317},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.8119999766349792},{"id":"https://openalex.org/keywords/treatment-quality","display_name":"treatment quality","score":0.734000027179718},{"id":"https://openalex.org/keywords/patient-safety","display_name":"patient safety","score":0.8740000128746033},{"id":"https://openalex.org/keywords/specialist-referral","display_name":"specialist referral","score":0.5049999952316284},{"id":"https://openalex.org/keywords/general-practitioners","display_name":"general practitioners","score":0.7749999761581421},{"id":"https://openalex.org/keywords/health-insurers","display_name":"health insurance companies","score":0.6899999976158142},{"id":"https://openalex.org/keywords/zorgverzekeraars-nederland","display_name":"Zorgverzekeraars Nederland","score":0.8899999856948853},{"id":"https://openalex.org/keywords/stakeholder-perspectives","display_name":"stakeholder perspectives","score":0.6039999723434448},{"id":"https://openalex.org/keywords/barriers-to-prescribing","display_name":"barriers to prescribing","score":0.49000000953674316},{"id":"https://openalex.org/keywords/dutch-healthcare-system","display_name":"Dutch healthcare system","score":0.5490000247955322},{"id":"https://openalex.org/keywords/health-technology-assessment","display_name":"health technology assessment","score":0.4690000116825104},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.39500001072883606},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.42500001192092896}],"concepts":[{"id":"https://openalex.org/C2779703844","wikidata":"https://www.wikidata.org/wiki/Q760125","display_name":"Reimbursement","level":3,"score":0.951005220413208},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.5483230352401733},{"id":"https://openalex.org/C56666940","wikidata":"https://www.wikidata.org/wiki/Q788790","display_name":"Documentation","level":2,"score":0.5232300162315369},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.49222078919410706},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4233362674713135},{"id":"https://openalex.org/C162118730","wikidata":"https://www.wikidata.org/wiki/Q1128453","display_name":"Actuarial science","level":1,"score":0.42043575644493103},{"id":"https://openalex.org/C2779530757","wikidata":"https://www.wikidata.org/wiki/Q1207505","display_name":"Quality (philosophy)","level":2,"score":0.41944870352745056},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.1245892345905304},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.10191860795021057},{"id":"https://openalex.org/C111472728","wikidata":"https://www.wikidata.org/wiki/Q9471","display_name":"Epistemology","level":1,"score":0.0},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:62627980","doi":null,"is_oa":false,"landing_page_url":"https://thesis.eur.nl/pub/12738/Buitenhuis%20R%20351371.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8371999859809875}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":9,"referenced_works":["https://openalex.org/W1565893470","https://openalex.org/W1984740259","https://openalex.org/W2000117884","https://openalex.org/W2046363656","https://openalex.org/W2070710390","https://openalex.org/W2088544591","https://openalex.org/W2155761001","https://openalex.org/W2159011964","https://openalex.org/W2169161528"],"related_works":["https://openalex.org/W2016724410","https://openalex.org/W7042615420","https://openalex.org/W2334696078","https://openalex.org/W4308174573","https://openalex.org/W2413330970","https://openalex.org/W2908159022","https://openalex.org/W2296211087","https://openalex.org/W2427255485","https://openalex.org/W2529795501","https://openalex.org/W7096275262"],"abstract_inverted_index":{"Summary\r\nBackground:":[0],"In":[1,35,93,523],"response":[2],"to":[3,23,30,62,88,133,184,201,214,263,273,285,302,363,407,456,490,496,532,545,596,615,627],"the":[4,36,38,55,81,86,94,100,111,121,144,147,154,174,186,204,216,219,235,265,321,325,338,346,377,402,408,414,435,444,463,471,501,508,516,542,553,579,592,603,617,631],"high":[5],"and":[6,48,68,195,226,256,291,332,367,381,387,394,427,450,512,564,607],"growing":[7],"costs":[8,25,47,194,328,361,511],"of":[9,44,50,57,80,97,156,188,197,218,312,317,371,383,392,410,429,572,633],"health":[10,33,117,254],"care,":[11],"governments":[12],"introduce":[13],"restrictive":[14],"drug":[15,350],"reimbursement":[16,91,95,159,171,190,205,221,270,279,458,472,517,535,554,636],"policies":[17,21],"on":[18,167,192,327,379,462,465,503,510,602],"drugs.":[19],"These":[20],"aim":[22],"contain":[24],"without":[26,630],"denying":[27],"patients\u2019":[28,594,625],"access":[29,299,489,544,595,626],"good":[31],"quality":[32,49,196,380,426,449],"care.":[34],"Netherlands,":[37],"balance":[39,145,445],"between":[40,146,446,562,605],"these":[41],"competing":[42,176],"aspect":[43],"healthcare":[45],"(access,":[46],"treatment)":[51],"are":[52,66,74,485,578],"safeguarded":[53],"by":[54,84,127,309,357,552],"Minister":[56],"Health":[58],"who":[59],"is":[60,165,183,307,452,537,548,611],"authorized":[61],"decide":[63],"which":[64,70],"drugs":[65,83,98],"reimbursed":[67,82,135],"under":[69],"conditions.":[71,92],"Additionally,":[72],"insurers":[73],"responsible":[75],"for":[76,105,136,283,300,417,582],"an":[77,313],"effective":[78],"application":[79],"having":[85],"authorization":[87],"apply":[89],"additional":[90,158,170,220,600],"case":[96],"from":[99,539],"GLP-1":[101,303,318,411,546,597,628],"receptor":[102],"agonist":[103],"class":[104],"Diabetes":[106],"Mellitus":[107],"Type":[108],"2":[109],"patients,":[110],"\u2018Zorgverzekeraars":[112],"Nederland":[113],"(ZN)\u2019":[114],"(representing":[115],"Dutch":[116],"insurers)":[118],"decided":[119],"that":[120,295,345,425,443,470,483,492,515,538,558],"first":[122],"prescription":[123],"must":[124,207],"be":[125,134,208,354,432,475,480,494,521],"prescribed":[126],"a":[128,141,231,274,297,358,368,559,570],"medical":[129],"specialist":[130],"in":[131,143,199,320,337,349,360,401,413,434,488,529,589,613,621],"order":[132,200,614],"patients.\r\nObjective:":[137],"Several":[138],"concerns":[139],"regarding":[140,507,575],"disturbance":[142],"three":[148,175],"societal":[149,177,257],"values":[150],"were":[151,228,244,261,293,335,399],"raised":[152],"after":[153],"introduction":[155],"ZN\u2019s":[157,169,189,269,278,457,534,635],"condition.":[160,222,459,555,637],"However,":[161,405,498],"limited":[162,298,543,593],"scientific":[163],"data":[164],"available":[166],"how":[168],"condition":[172,191,206,473,518,536],"affects":[173],"values.":[178],"Therefore,":[179,599],"this":[180,422,440,525],"study\u2019s":[181,526],"objective":[182],"evaluate":[185],"impact":[187,217,326,378,464,502,509],"access,":[193,447,466,504],"treatment":[198,415,430,491],"identify":[202,215],"whether":[203],"removed.\r\nMethods:":[209],"Qualitative":[210],"research":[211,601],"was":[212],"performed":[213],"First,":[223,439],"relevant":[224],"literature":[225],"documentation":[227],"studied":[229],"during":[230],"6-month":[232],"internship":[233],"at":[234],"pharmaceutical":[236],"company":[237],"Eli":[238],"Lilly.":[239],"Subsequently,":[240],"thirteen":[241],"semi-structured":[242],"interviews":[243],"conducted":[245],"with":[246,248,390,569],"stakeholders":[247,260],"different":[249],"perspectives,":[250],"i.e.":[251],"patient,":[252],"physician,":[253],"insurance":[255],"perspective.":[258],"The":[259],"asked":[262],"compare":[264],"\u2018current\u2019":[266],"situation":[267,276],"(with":[268],"condition)":[271],"compared":[272],"\u2018fictive\u2019":[275],"(without":[277],"condition).\r\nResults:":[280],"Three":[281],"barriers":[282],"GPs":[284,393],"refer":[286],"patients":[287,301,484],"(i.e.":[288],"financial,":[289],"cultural":[290],"professional)":[292],"identified":[294],"suggest":[296,469],"therapy.":[304,598],"This":[305,341],"suggestion":[306],"strengthened":[308],"stakeholders\u2019":[310],"expectation":[311],"absolute":[314],"volume":[315],"increase":[316,348],"therapy":[319,412,547,629],"fictive":[322,339,403,436],"situation.":[323,340,404,437],"Evaluating":[324],"both":[329,385],"cost":[330,351],"increasing":[331],"decreasing":[333],"factors":[334],"expected":[336,347,400],"thesis,":[342],"however,":[343],"suggests":[344,424],"would":[352,479,623],"only":[353],"partially":[355],"offset":[356],"reduction":[359],"related":[362],"consults,":[364],"productivity,":[365],"co-morbidity":[366],"decreased":[369],"number":[370],"glucose":[372],"test":[373],"strips.":[374],"Finally,":[375],"evaluating":[376],"safety":[382,428,451],"treatment,":[384],"improvements":[386],"deterioration":[388],"associated":[389],"characteristics":[391],"2nd":[395,565,608],"line":[396,419,566,584,609],"physician":[397,610],"care":[398],"due":[406,455],"absence":[409],"guidelines":[416],"1st":[418,563,583,606],"physicians":[420],"(NHG),":[421],"thesis":[423],"cannot":[431],"guaranteed":[433],"\r\nConclusion:":[438],"study":[441],"demonstrated":[442],"costs,":[448],"currently":[453,486],"disturbed":[454],"Focusing":[460],"mainly":[461],"one":[467],"could":[468],"should":[474,519],"removed":[476],"since":[477],"it":[478],"highly":[481],"improper":[482],"hindered":[487],"might":[493],"beneficial":[495],"them.":[497],"looking":[499],"beyond":[500],"our":[505,540],"suggestions":[506],"quality/safety":[513],"indicated":[514],"not":[520,531,549],"removed.":[522],"addition,":[524],"most":[527],"consideration":[528],"deciding":[530],"remove":[533],"opinion":[541],"necessarily":[550],"caused":[551],"We":[556],"believe":[557],"poor":[560],"collaboration":[561],"physicians,":[567],"together":[568],"lack":[571],"solid":[573],"agreements":[574],"referral":[576,586,618],"criteria,":[577],"fundamental":[580],"reasons":[581],"physicians\u2019":[585],"barriers,":[587,619],"which,":[588,620],"turn":[590,622],"induce":[591],"cooperation":[604],"recommended":[612],"dissolve":[616],"increases":[624],"need":[632],"removing":[634]},"counts_by_year":[{"year":2014,"cited_by_count":1}],"updated_date":"2025-11-06T04:12:42.849631","created_date":"2016-06-24T00:00:00"}